Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
Status:
Completed
Trial end date:
2020-10-17
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess
the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with
placebo + SoC therapy, in patients aged ≥12 years with COVID-19 disease.